1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

TABLE 2:

MR Imaging and SPECT findings in nine patients with DAVF hyperintensity on T2-Weighted MR Images

PatientBefore Treatmen FindingsAfter Treatment FindingsOutcome
T2-Weighted MR ImagingSPECTT2-Weighted MR ImagingSPECT
At RestWith AcetazolamideAt RestWith Acetazolamide
Type 2a
 12HyperintensityHypoperfusionPreservedT2-normalization at 1 moNormalNot doneGood
 13HyperintensityHypoperfusionPreservedT2-normalization at 2 wkNormalNot doneGood
 14HyperintensityHypoperfusionPreservedT2-normalization at 2 wkNormalNot doneGood
 15HyperintensityHypoperfusionPreservedT2-normalization at 1 wkNormalNot doneGood
 16HyperintensityHypoperfusionPreservedT2-normalization at 3 wkNormalNot doneGood
 17HyperintensityHypoperfusionPreservedT2-normalization at 2 wkNormalNot doneGood
 18HyperintensityHypoperfusionPreservedT2-normalization at 3 wkNormalNot doneGood
Type 2b
 19HyperintensityHypoperfusionNon-preservedT2-hyperintensity continued, subcortical hemorrhageHypoperfusion, peripheral hyperperfusionNon-preservedPoor
 20HyperintensityHypoperfusionNon-preservedT2-hyperintensity continuedHypoperfusionNon-preservedPoor
 21HyperintensityHypoperfusionNon-preservedT2-hyperintensity continuedHypoperfusionNon-preservedPoor
 22HyperintensityHypoperfusionNon-preservedT2-hyperintensity continuedHypoperfusionNon-preservedPoor